keyword
MENU ▼
Read by QxMD icon Read
search

Brain tumor chemotherapy

keyword
https://www.readbyqxmd.com/read/28723673/energy-metabolism-in-glioblastoma-stem-cells-ppar%C3%AE-a-metabolic-adaptor-to-intratumoral-microenvironment
#1
Alessia Fidoamore, Loredana Cristiano, Chiara Laezza, Renato Galzio, Elisabetta Benedetti, Benedetta Cinque, Andrea Antonosante, Michele d'Angelo, Vanessa Castelli, Maria Grazia Cifone, Rodolfo Ippoliti, Antonio Giordano, Annamaria Cimini
Glioblastoma (GB), the most-common cancer in the adult brain, despite surgery and radio/ chemotherapy, is to date almost incurable. Many hypoxic tumors, including GB, show metabolic reprogramming to sustain uncontrolled proliferation, hypoxic conditions and angiogenesis. Peroxisome Proliferator-activated Receptors (PPAR), particularly the α isotype, have been involved in the control of energetic metabolism. Herein, we characterized patient-derived GB neurospheres focusing on their energetic metabolism and PPARα expression...
July 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28723281/imaging-correlates-of-adult-glioma-genotypes
#2
Marion Smits, Martin J van den Bent
Primary brain tumors, most commonly gliomas, are histopathologically typed and graded as World Health Organization (WHO) grades I-IV according to increasing degrees of malignancy. These grades provide prognostic information and guidance on treatment such as radiation therapy and chemotherapy after surgery. Despite the confirmed value of the WHO grading system, results of a multitude of studies and prospective interventional trials now indicate that tumors with identical morphologic criteria can have highly different outcomes...
August 2017: Radiology
https://www.readbyqxmd.com/read/28720549/evolutionary-basis-of-a-new-approach-for-the-treatment-of-malignant-brain-tumors-from-mice-to-humans
#3
Pedro R Lowenstein, Maria G Castro
Glioma cells are one of the most aggressive and malignant tumors. Following initial surgery, and radio-chemotherapy they progress rapidly, so that patients' median survival remains under two years. They invade throughout the brain, which makes them difficult to treat, and are universally lethal. Though total resection is always attempted it is not curative. Standard of care in 2016 comprises surgical resection, radiotherapy and chemotherapy (temozolomide). Median survival is currently ~14-20months post-diagnosis though it can be higher in high complexity medical university centers, or during clinical trials...
July 15, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28715490/patterns-of-care-of-brain-tumor-related-epilepsy-a-cohort-study-done-in-italian-epilepsy-center
#4
Marta Maschio, Ettore Beghi, Marina M L Casazza, Gabriella Colicchio, Cinzia Costa, Paola Banfi, Stefano Quadri, Paolo Aloisi, Anna Teresa Giallonardo, Carla Buttinelli, Giada Pauletto, Salvatore Striano, Andrea Salmaggi, Riccardo Terenzi, Ornella Daniele, Giovanni Crichiutti, Francesco Paladin, Rosario Rossi, Giulia Prato, Federico Vigevano, Roberto De Simone, Federica Ricci, Marina Saladini, Fabrizio Monti, Susanna Casellato, Tiziano Zanoni, Diana Giannarelli, Giuliano Avanzini, Umberto Aguglia
Epilepsy is the most common comorbidity in patients with brain tumors. STUDY AIMS: To define characteristics of brain tumor-related epilepsy (BTRE) patients and identify patterns of care. Nationwide, multicenter retrospective cohort study. Medical records of BTRE patients seen from 1/1/2010 to 12/31/2011, followed for at least one month were examined. Information included age, sex, tumor type/treatments, epilepsy characteristics, antiepileptic drugs (AEDs). Time to modify first AED due to inefficacy and/or toxicity was assessed with the Kaplan-Meier method and Cox proportional hazard models were used to identify predictors of treatment outcome...
2017: PloS One
https://www.readbyqxmd.com/read/28713019/glioma-sensitive-or-chemoresistant-to-temozolomide-differentially-modulate-macrophage-protumor-activities
#5
Juliana H Azambuja, Elita F da Silveira, Taíse R de Carvalho, Pathise S Oliveira, Simone Pacheco, Carlus T do Couto, Fátima T Beira, Francieli M Stefanello, Rosélia M Spanevello, Elizandra Braganhol
BACKGROUND: Glioblastomas are the most devastating brain tumor characterized by chemoresistance development and poor prognosis. Macrophages are a component of tumor microenvironment related to glioma malignancy. The relation among inflammation, innate immunity and cancer is accepted; however, molecular and cellular mechanisms mediating this relation and chemoresistance remain unresolved. OBJECTIVE: Here we evaluated whether glioma sensitive or resistant to temozolomide (TMZ) modulate macrophage polarization and inflammatory pathways associated...
July 13, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28712904/pitfalls-in-diagnosis-and-management-of-testicular-choriocarcinoma-metastatic-to-the-brain-report-of-two-cases-and-review-of-literature
#6
REVIEW
Haydn Hoffman, Gentian Toshkezi, Joseph M Fullmer, Walter Hall, Lawrence S Chin
INTRODUCTION: Pure choriocarcinoma of the testes is a rare, aggressive germ cell tumor (GCT) that can metastasize to the brain. Although its prognosis has improved with the development of cisplatin-based chemotherapy regimens, cerebral metastases are prone to hemorrhage and are associated with high morbidity. Here, we present two cases of testicular choriocarcinoma with cerebral metastasis and discuss potential pitfalls in their diagnosis and management. We also review cases in the literature that feature these rare lesions...
July 13, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28707595/functional-roles-of-the-ca2-activated-k-channel-kca3-1-in-brain-tumors
#7
Giuseppina D Alessandro, Cristina Limatola, Myriam Catalano
Glioblastoma is the most aggressive and deadly brain tumor, with low disease-free period even after surgery and combined radio and chemotherapies. Among the factors contributing to rapid tumor growth in the brain are the elevated proliferation and invasion rate, and the ability to induce a local immunosuppressive environment. The intermediate-conductance Ca2+-activated K+ channel KCa3.1 is expressed on glioblastoma cells and in tumor-infiltrating cells. In tumor cells, the functional expression of KCa3.1 is important to modulate cell invasion and proliferation...
July 13, 2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/28700357/are-three-weeks-hypofractionated-radiation-therapy-hfrt-comparable-to-six-weeks-for-newly-diagnosed-glioblastoma-patients-results-of-a-phase-ii-study
#8
Pierina Navarria, Federico Pessina, Stefano Tomatis, Riccardo Soffietti, Marco Grimaldi, Egesta Lopci, Arturo Chiti, Antonella Leonetti, Alessandra Casarotti, Marco Rossi, Luca Cozzi, Anna Maria Ascolese, Matteo Simonelli, Simona Marcheselli, Armando Santoro, Elena Clerici, Lorenzo Bello, Marta Scorsetti
BACKGROUND: The current standard of care for newly diagnosed glioblastoma (GBM) is surgical resection, followed by radiation therapy (RT) with concurrent and adjuvant temozolomide chemotherapy (TMZ-CHT).. The patients outcome is still poor. In this study we evaluated hypofractionated radiation therapy (HFRT), instead of standard fractionated radiation therapy, with concomitant and adjuvant TMZ chemotherapy, in terms of safety and effectiveness. METHODS: Patients with newly diagnosed GBM, Karnofsky performance scale (KPS) ≥70, and tumor up to 10 cm underwent maximal feasible surgical resection were treated...
June 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28696366/role-and-therapeutic-targeting-of-the-hgf-met-pathway-in-glioblastoma
#9
REVIEW
Nichola Cruickshanks, Ying Zhang, Fang Yuan, Mary Pahuski, Myron Gibert, Roger Abounader
Glioblastoma (GBM) is a lethal brain tumor with dismal prognosis. Current therapeutic options, consisting of surgery, chemotherapy and radiation, have only served to marginally increase patient survival. Receptor tyrosine kinases (RTKs) are dysregulated in approximately 90% of GBM; attributed to this, research has focused on inhibiting RTKs as a novel and effective therapy for GBM. Overexpression of RTK mesenchymal epithelial transition (MET), and its ligand, hepatocyte growth factor (HGF), in GBM highlights a promising new therapeutic target...
July 11, 2017: Cancers
https://www.readbyqxmd.com/read/28696016/central-nervous-system-relapse-of-rhabdomyosarcoma
#10
Brian De, Michael D Kinnaman, Leonard H Wexler, Kim Kramer, Suzanne L Wolden
PURPOSE: The optimal management of central nervous system (CNS) relapse of rhabdomyosarcoma (RMS) is unclear. We examined diagnosis, management, and outcomes of patients with RMS developing CNS relapse. METHODS: Records of 23 patients diagnosed with CNS relapse between 1999 and 2016 were reviewed. Median age at presentation of CNS relapse was 15 years (range, 1-34 years). High-risk features at initial presentation were as follows: 16 alveolar patients, 13 Stage IV, and 13 with primary tumor in parameningeal locations...
July 11, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28693284/%C3%AE-human-chorionic-gonadotropin-secreting-intracranial-germ-cell-tumor-associated-with-high-testosterone-in-an-adult-man-a-case-report
#11
Wen-Ping Yang, Hung-Yu Chien, Yi-Chun Lin
A 38-year-old male patient presented with general weakness, polydipsia and a body weight loss of 10 kg in two years. Hypopituitarism with central hypothyroidism and central adrenal insufficiency were noted at Taipei City Hospital (Taipei, Taiwan). However, hypogonadotropic hypergonadism was also observed. The patient was diagnosed with an intracranial β-human chorionic gonadotropin (β-hCG) secreting germ-cell tumor, and brain magnetic resonance imaging revealed that the tumor involved the pineal gland, stalk, posterior pituitary gland, right basal ganglion, hypothalamus, corpus callosum and posterior hippocampus...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28690660/a-case-of-breast-cancer-brain-metastasis-with-a-16-year-time-interval-without-evidence-of-cancer-recurrence
#12
Shoko Merrit Yamada, Yusuke Tomita, Soichiro Shibui, Takashi Kurokawa, Yasuhisa Baba
The median time of brain metastasis from the diagnosis of breast cancer is approximately 3 years. In this case report, a 69-year-old woman demonstrated cerebellar ataxia. Brain magnetic resonance imaging revealed enhanced lesions in bilateral cerebellar hemispheres. She had undergone surgery, radiation, and chemotherapy for uterine and breast cancer 24 years prior and 16 years prior, respectively. Although she had not received any anticancer treatment for 10 years, no recurrences were identified using whole body scans...
June 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28690586/modulations-in-the-peripheral-immune-system-of-glioblastoma-patient-is-connected-to-therapy-and-tumor-progression-a-case-report-from-the-immo-glio-01-trial
#13
Paul F Rühle, Nicole Goerig, Roland Wunderlich, Rainer Fietkau, Udo S Gaipl, Annedore Strnad, Benjamin Frey
Immune responses are important for efficient tumor elimination, also in immune privileged organs such as the brain. Fostering antitumor immunity has therefore become an important challenge in cancer therapy. This cannot only be achieved by immunotherapies as already standard treatments such as radiotherapy and chemotherapy modify the immune system. Consequently, the understanding of how the tumor, the tumor microenvironment, and immune system are modulated by cancer therapy is required for prognosis, prediction, and therapy adaption...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28687906/development-of-the-implantable-resonator-system-for-clinical-epr-oximetry
#14
Rose M Caston, Wilson Schreiber, Huagang Hou, Benjamin B Williams, Eunice Y Chen, Philip E Schaner, Lesley A Jarvis, Ann Barry Flood, Sergey V Petryakov, Maciej M Kmiec, Periannan Kuppusamy, Harold M Swartz
Hypoxic tumors are more resistant to radiotherapy and chemotherapy, which decreases the efficacy of these common forms of treatment. We have been developing implantable paramagnetic particulates to measure oxygen in vivo using electron paramagnetic resonance. Once implanted, oxygen can be measured repeatedly and non-invasively in superficial tissues (<3 cm deep), using an electron paramagnetic resonance spectrometer and an external surface-loop resonator. To significantly extend the clinical applications of electron paramagnetic resonance oximetry, we developed an implantable resonator system to obtain measurements at deeper sites...
July 7, 2017: Cell Biochemistry and Biophysics
https://www.readbyqxmd.com/read/28687190/a-synthetic-bmp-2-mimicking-peptide-induces-glioblastoma-stem-cell-differentiation
#15
Elena Rampazzo, Monica Dettin, Francesca Maule, Alessandra Scabello, Luisa Calvanese, Gabriella D'Auria, Lucia Falcigno, Elena Porcù, Annj Zamuner, Alessandro Della Puppa, Daniele Boso, Giuseppe Basso, Luca Persano
BACKGROUND: Glioblastoma (GBM) is the most aggressive type of primary brain tumor, characterized by the intrinsic resistance to chemotherapy due to the presence of a highly aggressive Cancer Stem Cell (CSC) sub-population. In this context, Bone Morphogenetic Proteins (BMPs) have been demonstrated to induce CSC differentiation and to sensitize GBM cells to treatments. METHODS: The BMP-2 mimicking peptide, named GBMP1a, was synthesized on solid-phase by Fmoc chemistry...
July 4, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28685086/outcomes-of-aggressive-treatment-in-esophageal-cancer-patients-with-synchronous-solitary-brain-metastasis
#16
Cem Onal, Berna Akkus Yildirim, Ozan Cem Guler
The aim of the present study was to investigate the outcomes of esophageal cancer (EC) patients with isolated synchronous brain oligometastasis (oligo-BM) treated with chemoradiotherapy (CRT) of the primary site and localized treatment of the BM with surgery, radiotherapy (RT) or radiosurgery. Of 125 EC patients investigated, seven patients (6%) had solitary BM. Six patients were diagnosed prior to, and one patient was diagnosed during, treatment. All patients were treated with neoadjuvant chemotherapy and whole-brain RT (WBRT) for BM...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28681349/pharmacotherapy-of-glioblastoma-established-treatments-and-emerging-concepts
#17
REVIEW
Enrico Franceschi, Santino Minichillo, Alba A Brandes
Glioblastoma is the most frequent malignant brain tumor and is characterized by poor prognosis, increased invasiveness, and high recurrence rates. Standard treatment for glioblastoma includes maximal safe surgical resection, radiation, and chemotherapy with temozolomide. Despite treatment advances, only 15-20% of glioblastoma patients survive to 5 years, and no therapies have demonstrated a durable survival benefit in recurrent disease. In the last 10 years, significant advances in knowledge of the biology and molecular pathology of the malignancy have opened the way to new treatment options...
July 5, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28675067/postoperative-neoadjuvant-temozolomide-before-radiotherapy-versus-standard-radiotherapy-in-patients-60-years-or-younger-with-anaplastic-astrocytoma-or-glioblastoma-a-randomized-trial
#18
Annika Malmström, Hans Skovgaard Poulsen, Bjørn Henning Grønberg, Giuseppe Stragliotto, Steinbjørn Hansen, Thomas Asklund, Birgitta Holmlund, Małgorzata Łysiak, Joseph Dowsett, Bjarne Winther Kristensen, Peter Söderkvist, Johan Rosell, Roger Henriksson
INTRODUCTION: A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We therefore investigated neoadjuvant TMZ (NeoTMZ) in a randomized trial. During enrollment, concomitant and adjuvant radio-chemotherapy with TMZ became standard treatment. The trial was amended to include concurrent TMZ. PATIENTS AND METHODS: Patients, after surgery for GBM or AA, age ≤60 years and performance status (PS) 0-2, were randomized to either 2-3 cycles of TMZ, 200 mg/m(2) days 1-5 every 28 days, followed by RT 60 Gy in 30 fractions or RT only...
July 4, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28672195/combination-treatment-with-the-gsk-3-inhibitor-9-ing-41-and-ccnu-cures-orthotopic-chemoresistant-glioblastoma-in-patient-derived-xenograft-models
#19
Andrey Ugolkov, Wenan Qiang, Gennadiy Bondarenko, Daniel Procissi, Irina Gaisina, C David James, James Chandler, Alan Kozikowski, Hendra Gunosewoyo, Thomas O'Halloran, Jeffrey Raizer, Andrew P Mazar
Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB-mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our objective was to determine the antitumor effect of GSK-3 inhibitor 9-ING-41 in combination with chemotherapy in patient-derived xenograft (PDX) models of human GBM. We utilized chemoresistant PDX models of GBM, GBM6 and GBM12, to study the effect of 9-ING-41 used alone and in combination with chemotherapy on tumor progression and survival...
June 30, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28668902/analysis-of-evolving-clinicopathological-features-of-metastatic-brain-tumors-over-30-years-of-surgical-management
#20
Hiromasa Kobayashi, Makoto Hamasaki, Takashi Morishita, Tooru Inoue, Kazuki Nabeshima
We reviewed 232 cases, in which patients underwent surgical resection and histopathological diagnosis of metastatic brain tumor between 1985 and 2014. We analyzed trends in clinicopathological changes present over three decades in a single institution. The most frequent site of metastatic tumors was the frontal lobe. The average patient age and the percentage of female patients increased over the 30-year study period. The most frequent primary cancer was lung cancer, followed by breast cancer; these were the top two primary cancer types over the three decades...
July 2017: Anticancer Research
keyword
keyword
120937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"